{"count": 5, "results": [{"_id": "24267260", "pmid": 24267260, "title": "Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects.", "journal": "Atherosclerosis", "authors": ["Sternberg Z", "Chichelli T", "Sternberg D", "Hojnacki D", "Drake A", "Liu S", "Hu Q", "Munschauer F"], "date": "2013-12-01T00:00:00Z", "doi": "10.1016/j.atherosclerosis.2013.09.031", "meta_date_publication": "2013 Dec", "meta_volume": "231", "meta_issue": "2", "meta_pages": "411-20", "score": 50087.086, "text_hl": "Quantitative and qualitative pleiotropic differences between @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ single and @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ combination therapy in @<m>DISEASE_Hyperlipoproteinemia_Type_II</m> @DISEASE_MESH:D006938 @@@hypercholesterolemic@@@ subjects.", "citations": {"NLM": "Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S, Hu Q, Munschauer F. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis. 2013 Dec;231(2):411-20. PMID: 24267260", "BibTeX": "@article{24267260, title={Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects.}, author={Sternberg Z and Chichelli T and Sternberg D and Hojnacki D and Drake A and Liu S and Hu Q and Munschauer F}, journal={Atherosclerosis}, volume={231}, number={2}, pages={411-20}}"}}, {"_id": "18420099", "pmid": 18420099, "title": "Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.", "journal": "J Am Coll Cardiol", "authors": ["Guyton JR", "Brown BG", "Fazio S", "Polis A", "Tomassini JE", "Tershakovec AM"], "date": "2008-04-22T00:00:00Z", "doi": "10.1016/j.jacc.2008.03.003", "meta_date_publication": "2008 Apr 22", "meta_volume": "51", "meta_issue": "16", "meta_pages": "1564-72", "score": 50075.97, "text_hl": "METHODS: In this 24-week multicenter, randomized, double-blind study, 1,220 @<m>DISEASE_Hyperlipoproteinemia_Type_II</m> @DISEASE_MESH:D006938 @@@type IIa or IIb hyperlipidemic@@@ @SPECIES_9606 @@@patients@@@ were randomized to treatment with @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ (10/20 mg/day) + @CHEMICAL_Nitrogen @CHEMICAL_MESH:D009584 @@@N@@@ (titrated to 2 g/day), or @CHEMICAL_Nitrogen @CHEMICAL_MESH:D009584 @@@N@@@ (titrated to 2 g/day), or @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ (10/20 mg/day). ", "citations": {"NLM": "Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. PMID: 18420099", "BibTeX": "@article{18420099, title={Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.}, author={Guyton JR and Brown BG and Fazio S and Polis A and Tomassini JE and Tershakovec AM}, journal={J Am Coll Cardiol}, volume={51}, number={16}, pages={1564-72}}"}}, {"_id": "23926117", "pmid": 23926117, "pmcid": "PMC3828803", "title": "Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Hyperlipidemic Patients", "journal": "J Am Heart Assoc", "authors": ["Le NA", "Jin R", "Tomassini JE", "Tershakovec AM", "Neff DR", "Wilson PW"], "date": "2013-08-07T00:00:00Z", "doi": "10.1161/JAHA.113.000037", "meta_date_publication": "2013 Aug 7", "meta_volume": "2", "meta_issue": "4", "meta_pages": "e000037", "score": 50065.21, "text_hl": "This was an analysis of a previously reported 24-week randomized, double-blind study in @<m>DISEASE_Hyperlipoproteinemia_Type_II</m> @DISEASE_MESH:D006938 @@@type IIa/IIb hyperlipidemic@@@ @SPECIES_9606 @@@patients@@@ randomized to treatment with @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ (10/20 mg/day)+@CHEMICAL_Nitrogen @CHEMICAL_MESH:D009584 @@@N@@@ (titrated to 2 g/day) or @CHEMICAL_Nitrogen @CHEMICAL_MESH:D009584 @@@N@@@ (titrated to 2 g/day) or @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ (10/20 mg/day). ", "citations": {"NLM": "Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW. Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Hyperlipidemic Patients J Am Heart Assoc. 2013 Aug 7;2(4):e000037. PMID: 23926117", "BibTeX": "@article{23926117, title={Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Hyperlipidemic Patients}, author={Le NA and Jin R and Tomassini JE and Tershakovec AM and Neff DR and Wilson PW}, journal={J Am Heart Assoc}, volume={2}, number={4}, pages={e000037}}"}}, {"_id": "24125402", "pmid": 24125402, "title": "Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.", "journal": "Atherosclerosis", "authors": ["Moutzouri E", "Liberopoulos EN", "Tellis CC", "Milionis HJ", "Tselepis AD", "Elisaf MS"], "date": "2013-11-01T00:00:00Z", "doi": "10.1016/j.atherosclerosis.2013.08.013", "meta_date_publication": "2013 Nov", "meta_volume": "231", "meta_issue": "1", "meta_pages": "8-14", "score": 50062.504, "text_hl": "We enrolled one hundred and fifty three (n = 153) @<m>DISEASE_Hyperlipoproteinemia_Type_II</m> @DISEASE_MESH:D006938 @@@hypercholesterolemic@@@ subjects who were randomized to receive @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 40 mg or @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ 10/10 mg or @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ 10 mg daily. ", "citations": {"NLM": "Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013 Nov;231(1):8-14. PMID: 24125402", "BibTeX": "@article{24125402, title={Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.}, author={Moutzouri E and Liberopoulos EN and Tellis CC and Milionis HJ and Tselepis AD and Elisaf MS}, journal={Atherosclerosis}, volume={231}, number={1}, pages={8-14}}"}}, {"_id": "28922021", "pmid": 28922021, "title": "Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia.", "journal": "Expert Opin Drug Metab Toxicol", "authors": ["Bove M", "Fogacci F", "Cicero AFG"], "date": "2017-10-01T00:00:00Z", "doi": "10.1080/17425255.2017.1381085", "meta_date_publication": "2017 Oct", "meta_volume": "13", "meta_issue": "10", "meta_pages": "1099-1104", "score": 50049.055, "text_hl": "Expert opinion: The synergistic action of these two drugs and the efficacy and safety extensively demonstrated of their association (in particular in the large IMProved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial -IMPROVE-IT-) promote its clinical use, especially in subjects with high cardiovascular risk who need to optimize their @<m>DISEASE_Hyperlipoproteinemia_Type_II</m> @DISEASE_MESH:D006938 @@@LDL-Cholesterolemia@@@, but also in @SPECIES_9606 @@@patients@@@ who cannot tolerate high-dose of more powerful statins.", "citations": {"NLM": "Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1099-1104. PMID: 28922021", "BibTeX": "@article{28922021, title={Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia.}, author={Bove M and Fogacci F and Cicero AFG}, journal={Expert Opin Drug Metab Toxicol}, volume={13}, number={10}, pages={1099-1104}}"}}]}